文献速递药疹与重症皮肤不良反应

免疫检查点抑制剂相关获得性全身性脂肪营养不良

Acquired generalized lipodystrophy under immune checkpoint inhibition.
PubMed 文献 · Br J Dermatol · 2019-08-09

本文报告一例47岁转移性黑色素瘤患者,接受抗PD-1抗体帕博利珠单抗治疗10个月后出现严重脂肪营养不良,表现为皮下脂肪丢失、中心性肥胖及伴瘦素降低的胰岛素抵抗。皮肤活检示皮下脂肪细胞破坏伴水肿、噬脂细胞及累及脂膜的CD3+淋巴细胞浸润,排除遗传及系统性自身免疫病后诊断为抗PD-1诱导的获得性全身性脂肪营养不良。未使用糖皮质激素,停用帕博利珠单抗后随访12个月,脂肪营养不良及严重代谢并发症仍持续。

要点

  • 抗PD-1治疗期间可发生获得性全身性脂肪营养不良,并伴严重代谢并发症。
  • 皮肤活检见脂肪细胞破坏、噬脂细胞及CD3+淋巴细胞浸润有助诊断。
  • 因代谢风险未用糖皮质激素,停药后代谢并发症仍可持续。

核心结论

  • 抗PD-1治疗可诱导获得性全身性脂肪营养不良,并伴严重代谢并发症,停药后仍可持续。

研究设计与样本

  • 个案报告:一例47岁转移性黑色素瘤患者接受帕博利珠单抗治疗10个月后出现脂肪营养不良。

主要发现

  • 治疗10个月后出现皮下脂肪丢失、中心性肥胖及伴瘦素降低的胰岛素抵抗。
  • 皮肤活检示皮下脂肪细胞破坏伴水肿、噬脂细胞及累及脂膜的CD3+淋巴细胞浸润。
  • 排除遗传及系统性自身免疫病后诊断为抗PD-1诱导的获得性全身性脂肪营养不良。
  • 停用帕博利珠单抗并随访12个月,脂肪营养不良及严重代谢并发症仍持续。

关键数值与推荐

  • 接受免疫检查点抑制剂患者中内分泌与皮肤irAEs分别占14-30%和30-40%。
  • 未使用糖皮质激素,考虑其诱发严重代谢并发症的高风险。

临床怎么用

  • 抗PD-1治疗期间需警惕获得性全身性脂肪营养不良及其代谢并发症。
  • 皮肤活检见脂肪细胞破坏、噬脂细胞及CD3+淋巴细胞浸润可支持诊断。
  • 是否使用糖皮质激素需权衡代谢并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors are now the standard of care in the treatment of several types of cancer. Cutaneous immune-related adverse events (irAEs) are usually of low grade and reversible, while endocrine irAEs are generally irreversible and managed with hormone replacement therapy. We report a 47-year-old patient, treated with the anti-programmed cell death (PD)1 antibody pembrolizumab for a metastatic melanoma, who developed severe lipodystrophy after 10 months of treatment, characterized by the loss of subcutaneous fat tissue, central obesity and insulin resistance with a decreased leptin level. Histological analysis of a cutaneous biopsy revealed subcutaneous fat cell destruction associated with oedema, the presence of lipophages, and a CD3+ lymphocytic infiltrate involving the panniculus. This led to the diagnosis of anti-PD-1-induced acquired generalized lipodystrophy, after ruling out differential diagnoses (i.e. genetic and systemic autoimmune diseases). No corticosteroids were introduced considering the high risk of inducing severe metabolic complications, and pembrolizumab was discontinued as complete response of the melanoma was achieved. However, after 12 months of follow-up, lipodystrophy and its severe metabolic complications are still ongoing. What's already known about this topic? Anti-programmed cell death (PD)1 agents are now a standard of care in the treatment of several cancers, including melanoma. Endocrine and cutaneous immune-related adverse events (irAEs) are among the most frequent irAEs (14-30% and 30-40%, respectively) in patients treated with immune checkpoint inhibitors. What does this study add? Acquired generalized lipodystrophy can occur during anti-PD1 therapy and is associated with severe metabolic complications. With the increase in anti-PD1 prescription in several cancer types, clinicians must be aware of the whole range of irAEs that may occur.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Haddad N, Vidal-Trecan T, Baroudjian B, et al. Acquired generalized lipodystrophy under immune checkpoint inhibition. Br J Dermatol. 2019. PMID: 31077337. doi:10.1111/bjd.18124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。